RESUMEN
SARS-CoV-2 emerged in December 2019 and led to the COVID-19 pandemic. Efforts to develop therapeutics have led to innovations such as mRNA vaccines and oral antivirals. Here we provide a narrative review of the biologic therapeutics used or proposed to treat COVID-19 during the last 3 years. This paper, along with its companion that covers xenobiotics and alternative remedies, is an update to our 2020 paper. Monoclonal antibodies prevent progression to severe disease, are not equally effective across variants, and are associated with minimal and self-limited reactions. Convalescent plasma has side effects like monoclonal antibodies, but with more infusion reactions and less efficacy. Vaccines prevent progression for a larger part of the population. DNA and mRNA vaccines are more effective than protein or inactivated virus vaccines. After mRNA vaccines, young men are more likely to have myocarditis in the subsequent 7 days. After DNA vaccines, those aged 30-50 are very slightly more likely to have thrombotic disease. To all vaccines we discuss, women are slightly more likely to have an anaphylactic reaction than men, but the absolute risk is small.
Asunto(s)
Anticuerpos Monoclonales , Sueroterapia para COVID-19 , COVID-19 , Inmunoterapia , Vacunas , Femenino , Humanos , Masculino , Anticuerpos Monoclonales/uso terapéutico , COVID-19/terapia , Pandemias/prevención & control , SARS-CoV-2RESUMEN
SARS-CoV-2 emerged in 2019 and led to the COVID-19 pandemic. Efforts to develop therapeutics against SARS-Cov-2 led to both new treatments and attempts to repurpose existing medications. Here, we provide a narrative review of the xenobiotics and alternative remedies used or proposed to treat COVID-19. Most repositioned xenobiotics have had neither the feared toxicity nor the anticipated efficacy. Repurposed viral replication inhibitors are not efficacious and frequently associated with nausea, vomiting, and diarrhea. Antiviral medications designed specifically against SARS-CoV-2 may prevent progression to severe disease in at-risk individuals and appear to have a wide therapeutic index. Colloidal silver, zinc, and ivermectin have no demonstrated efficacy. Ivermectin has a wide therapeutic index but is not efficacious and acquiring it from veterinary sources poses additional danger. Chloroquine has a narrow therapeutic index and no efficacy. A companion review covers vaccines, monoclonal antibodies, and immunotherapies. Together, these two reviews form an update to our 2020 review.
Asunto(s)
COVID-19 , Humanos , SARS-CoV-2 , Xenobióticos , Pandemias/prevención & control , Ivermectina/uso terapéutico , Antivirales/uso terapéuticoRESUMEN
Plant extracts and other novel psychoactives can be ingested, vaped, injected, or insufflated. This includes products such as extracts from the blue lotus flower (Nypmhaea caerulea), which is known to produce euphoria and hallucinations at high doses. Blue lotus is sold in several forms, including dried plant material, teas, and extracts for use in electronic cigarettes. Because newer generations of electronic cigarettes can deliver a variety of substances, practitioners need to be mindful of toxicity from a growing number of psychoactives, some of which are not detectable by standard urine drug screens. This case series describes five active duty patients who presented to the emergency department with altered mental status following the use of blue lotus products, four after vaping and one after making an infused beverage. Patients displayed similar symptoms, including sedation and perceptual disturbances. The patients in our series were successfully managed with supportive measures without the need for sedating agents. Recognizing and identifying new trends in substance use can help to provide directions in undifferentiated altered mental status.
RESUMEN
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.
Asunto(s)
Antivirales/toxicidad , Antivirales/uso terapéutico , Cloroquina/toxicidad , Cloroquina/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Hidroxicloroquina/toxicidad , Hidroxicloroquina/uso terapéutico , Neumonía Viral/tratamiento farmacológico , Betacoronavirus/efectos de los fármacos , COVID-19 , Humanos , Pandemias , SARS-CoV-2 , Estados UnidosRESUMEN
BACKGROUND: Clonidine is a centrally-acting α-2 agonist used in the treatment of hypertension and attention-deficit/hyperactivity disorder, among other off-label uses. In overdose, it can cause sedation, bradycardia, and hypotension. Clonidine can be compounded as a liquid formula for patients who are unable to take pills, however, this can add to the risk of dosing errors. CASE REPORT: A 12-year-old boy diagnosed with autism, prescribed buspirone and clonidine, presented to the emergency department for altered mental status. His examination revealed generalized sedation, bradycardia (heart rate 30-40 beats/min), and hypotension (blood pressure 82/48 mm Hg). Resuscitation included i.v. crystalloids and multiple doses of atropine. Over the next 24 h, his vital signs and mental status normalized. He displayed no infectious symptoms or focal neurologic deficits. His parents noted that his medications had been refilled recently at the compounding pharmacy; because he was unable to take pills, his medications were in liquid formulation. Because his signs and symptoms were suspicious for a central α-2 agonist overdose, his clonidine preparation was sent to a reference laboratory for analysis. This analysis revealed the concentration was approximately eight times higher than indicated on its label. WHY SHOULD AND EMERGENCY PHYSICIAN BE AWARE OF THIS?: Compounding pharmacy errors can be a source of toxicity, even if there is no known history of an overdose. Recognizing the toxidrome of sedation, respiratory depression, bradycardia, hypotension, and miosis will lead to appropriate treatment of the patient and should prompt an investigation of the medication error to prevent further harm.